Core Viewpoint - The company reported a revenue of 229 million, reflecting a year-on-year increase of 2.67%, while the loss attributable to equity shareholders decreased by 96.17% to 2.163 million [1] Financial Performance - Revenue for the six months ending June 30, 2025, was 229 million, up 2.67% year-on-year [1] - Loss attributable to equity shareholders was 2.163 million, a significant reduction of 96.17% compared to the previous year [1] - Basic loss per share was 0.09 cents [1] Business Development - The increase in revenue was primarily driven by the ongoing global commercialization of the VitaFlow Liberty transcatheter aortic valve and its retrievable delivery system, which significantly boosted overseas revenue [1] - The commercialization progress of the AnchorMan left atrial appendage occlusion system and the AnchorMan left atrial appendage guiding system in both China and overseas markets is steadily advancing [1]
心通医疗-B发布中期业绩，股东应占亏损216.3万元，同比减少96.17%